TMPRSS6 Inhibitor

Sapablursen, an antisense oligonucleotide, is designed to reduce the production of TMPRSS6 resulting in increased expression of hepcidin, which is the key regulator of iron homeostasis. Sapablursen can be used in the research of blood diseases such as pol

Manusiran sodium scrambled negative control is the sequence scrambled negative control of Manusiran sodium.

SARSi-4 sodium scrambled negative control is the sequence scrambled negative control of SARSi-4 sodium.

Sapablursen sodium, an antisense oligonucleotide, is designed to reduce the production of TMPRSS6 resulting in increased expression of hepcidin, which is the key regulator of iron homeostasis. Sapablursen sodium can be used in the research of blood diseas

Manusiran (SLN124) sodium, a GalNAc conjugated 19-mer siRNA targeting TMPRSS6 (transmembrane protease serine 6), reduces plasma iron and increases hepcidin levels^[1][2].

Manusiran (Divesiran) is a GalNac-siRNA targeting liver and transmembrane serine protease 6 (Serine protease 6). Manusiran increases hepatic Hepcidin synthesis and plasma levels by silencing TMPRSS6, a negative regulator of hepcidin production, and limits the availability of iron required for erythropoiesis. Combined use of Manusiran with Deferiprone (HY-B0568) reduces ineffective erythropoiesis and hepatic iron overload in a mouse model of β-thalassemia. Manusiran can be used for research on polycythemia vera, type 1 hereditary hemochromatosis, and β-thalassemia.

WGU55 is a selective and potent reversible type II transmembrane serine protease TMPRSS6 inhibitor with a K_i of 12.15 nM. WGU55 inhibits TMPRSS6 activity with an IC₅₀ of 138 nMin KEK293 cells. WGU55 has a K_i of 3510 nM (SI = 289) against the homologous protease matriptase and a K_i of 5.2 μM against the coagulation key protease Factor Xa. WGU55 can be used for the research of iron overload related diseases, such as hereditary hemochromatosis.